Literature DB >> 31117106

Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens.

Stefano Partelli1,2, Fabio Giannone1, Marco Schiavo Lena3, Francesca Muffatti1,2, Valentina Andreasi1,2, Stefano Crippa1,2, Domenico Tamburrino1, Giuseppe Zamboni4, Corrado Rubini5, Claudio Doglioni3,2, Massimo Falconi6,7.   

Abstract

BACKGROUND/AIMS: The annual incidence of pancreatic neuroendocrine tumors (PanNET) has been estimated to be around 0.8/100,000 inhabitants. The aim of this study was to determine the frequency of incidental histological diagnosis of PanNET in pancreatic specimen evaluation for a purpose other other than PanNET diagnosis.
METHODS: One thousand seventy-four histopathological examinations of pancreatic specimens performed in 3 centers in Italy were retrospectively reviewed. All cases with a main pathological diagnosis of PanNET were excluded.
RESULTS: An incidental associated diagnosis of PanNET was made in 41 specimens (4%). Among those 41 cases, 29 (71%) had a largest diameter <5 mm (microadenoma), whereas the other 12 (29%) had a maximum size ≥5 mm (median diameter of the whole series = 3 mm, range 1-15). The association with a main diagnosis of intraductal papillary mucinous neoplasms (IPMN) was significantly higher for patients who had an incidental PanNET (p = 0.048). There was no association between incidental diagnosis of PanNET and age, gender, BMI, smoking habit, diabetes, and type of operation.
CONCLUSIONS: The frequency of incidental histological diagnosis of PanNET is considerably high, suggesting that their real prevalence is probably underestimated. The present study suggests a possible correlation between the incidental occurrence of PanNET and IPMN.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Histology; Incidental diagnosis; Pancreatic neuroendocrine tumor

Mesh:

Year:  2019        PMID: 31117106     DOI: 10.1159/000499606

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

Review 1.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

2.  Landmark Series: Importance of Pancreatic Resection Margins.

Authors:  Mihir M Shah; Jashodeep Datta; Nipun B Merchant; David A Kooby
Journal:  Ann Surg Oncol       Date:  2022-01-05       Impact factor: 5.344

Review 3.  Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Authors:  Gabriel Benyomo Mpilla; Philip Agop Philip; Bassel El-Rayes; Asfar Sohail Azmi
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

4.  Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification.

Authors:  Matteo Tacelli; Maria Chiara Petrone; Gabriele Capurso; Francesca Muffatti; Valentina Andreasi; Stefano Partelli; Claudio Doglioni; Massimo Falconi; Paolo Giorgio Arcidiacono
Journal:  Endosc Ultrasound       Date:  2021 Sep-Oct       Impact factor: 5.628

5.  A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.

Authors:  Przemysław Soczomski; Beata Jurecka-Lubieniecka; Aleksandra Krzywon; Alexander Jorge Cortez; Stanisław Zgliczynski; Natalia Rogozik; Małgorzata Oczko-Wojciechowska; Agnieszka Pawlaczek; Tomasz Bednarczuk; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

6.  Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).

Authors:  F Panzuto; M Maccauro; D Campana; A Faggiano; S Massironi; S Pusceddu; F Spada; D Ferone; R Modica; C M Grana; P Ferolla; M Rinzivillo; G Badalamenti; M C Zatelli; F Gelsomino; E De Carlo; M Bartolomei; M P Brizzi; S Cingarlini; A Versari; G Fanciulli; E Arvat; E Merola; M Cives; S Tafuto; S Baldari; M Falconi
Journal:  J Endocrinol Invest       Date:  2020-08-16       Impact factor: 4.256

7.  Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.

Authors:  Liwen Hong; Yuan Wang; Tianyu Zhang; Chen Zhang; Lei Wang; Liying Wang; Zhengting Wang; Jie Zhong
Journal:  Med Sci Monit       Date:  2020-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.